Curated news and analysis on clinical trials, drug approvals, and medical research.
Telix Pharmaceuticals has submitted regulatory applications for TLX101-Px, a brain cancer imaging agent, to both the European Medicines Agency and the U.S. Food and Drug Administration, seeking approval for glioma diagnosis and treatment monitoring.
Three recent studies reveal connections between gut microbiome composition and health outcomes, identifying specific bacterial groups associated with recovery and disease, plus genetic variants that shape microbial communities.
Savara has submitted a Biologics License Application for MOLBREEVI to the FDA with Priority Review status, targeting an August 22, 2026 decision date for treating autoimmune pulmonary alveolar proteinosis.
CAR T-cell therapy is delivering unprecedented results for multiple myeloma patients, with CARTITUDE-1 trial data showing one-third of patients remaining progression-free for five years or more, raising the possibility of cure for some patients.
Regulatory incentives for rare disease treatments, including market exclusivity and development subsidies, are spurring pharmaceutical innovation across the US, Europe, Japan, and Australia, with multiple companies advancing therapies for conditions affecting limited patient populations.
Novartis reported annual operating income of $17.07 billion for 2025, up 17.40% year-over-year, while AlphaValue/Baader raised its price target to 136 Swiss francs but maintained a "reduce" rating due to valuation concerns.
GLP-1 receptor agonists like semaglutide and tirzepatide help regulate appetite and improve satiety for medical weight loss. Clinical studies show patients can lose an average of 15% of body weight with these treatments. These medications are suitable for individuals with BMI of 27+ with weight-related conditions or BMI of 30+ regardless of other conditions.
Intuitive Surgical disclosed that an unauthorized third party accessed internal IT business applications through a phishing incident, while Medtronic plans to lay off 81 employees from its Diabetes unit ahead of the MiniMed separation.
Cogent Biosciences is preparing parallel FDA submissions for bezuclastinib across three indications following positive pivotal trial results, with potential launches beginning in late 2026 and full commercialization expected by early 2027.
New research demonstrates RNA therapies can enhance heart regeneration after injury, while RNA biomarkers improve prediction of cardiovascular complications in chronic kidney disease patients.
New research reveals how ketamine rewires brain receptors to rapidly relieve severe depression, while separate trials demonstrate success with personalized brain stimulation and targeted drug therapy for treatment-resistant cases.
New research demonstrates that blood tests measuring p-tau217 protein can identify dementia risk up to 25 years before symptoms and significantly improve diagnostic accuracy in clinical practice.
Immunic Inc presented additional data from its Phase 2 CALIPER trial at the ACTRIMS Forum, showing Vidofludimus calcium reduced both acute and chronic brain lesions in progressive multiple sclerosis patients and demonstrated clinical evidence of reduced EBV reactivation.
Healthcare leaders report precision medicine is becoming a clinical standard as AI tools emerge as "digital co-workers" and breakthroughs in biomarkers move beyond specialized oncology into primary care settings.
iSpecimen Inc. introduced an AI-powered Inventory Agent to accelerate biospecimen request matching on its marketplace platform. The tool uses large language models to process research requests and identify available inventory matches.
New clinical evidence demonstrates that combining SGLT2 inhibitors with GLP-1 receptor agonists provides additive benefits for type 2 diabetes patients, while machine learning tools help personalize therapy selection.
YolTech Therapeutics received FDA approval for its IND application for YOLT-202, an in vivo gene-editing therapy for Alpha-1 Antitrypsin Deficiency. Interim data from an ongoing trial showed rapid increases in AAT levels to normal range with favorable safety.
Nektar Therapeutics is advancing its immunology pipeline with plans to initiate Phase 3 trials for REZPEG in atopic dermatitis next quarter, following positive Phase 2b results. The company recently completed a large equity raise to support its regulatory T cell-focused programs.
Sen. Josh Hawley and Rep. Diana Harshbarger introduced legislation to withdraw FDA approval of mifepristone nationwide, making distribution a federal violation and allowing patients to sue manufacturers.
Recent research explores outcomes when patients stop GLP-1 medications and finds pharmacist-led interventions can help older adults avoid dangerous low blood sugar episodes.
